RXi Pharmaceuticals Corp - RXII - Financial Statement Analysis
All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.
In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.
Financial statement analysis updated: December 8, 2013
RXi Pharmaceuticals Corp - SIC # 2834
|Ticker||Exchange||SIC #||Website||Latest Ticker|
|RXII||Over the counter||2834||http://www.rxipharma.com/||2.91 0.00|
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for RXi Pharmaceuticals Corp
RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period - Dec 4th, 2013 6:05 am
Galena Biopharma to Present at the Oppenheimer 24th Annual Healthcare Conference - Dec 4th, 2013 5:21 am
Rxi Pharmaceuticals, Significant Upside Of 300% Is Expected In Coming Months - Dec 3rd, 2013 7:56 am
View All Current Headlines >>